Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

Jul 20, 2022

Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding

Jul 5, 2022

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

May 24, 2022

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting

May 23, 2022

Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results

May 12, 2022

Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update

May 5, 2022

Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

Apr 20, 2022

Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets

Apr 20, 2022

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis

Apr 19, 2022

Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India

Apr 18, 2022
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...43
    © 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap